A Phase 2 interventional study of 8 cycles BEACOPPesc plus oral contraceptive and 8 cycles BEACOPPesc plus Goserelin in Hodgkins Lymphoma, sponsored by University of Cologne. Completed. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2012-06-25.
Sponsored by University of Cologne · Phase 2, Interventional, and Treatment
This study is designed to test the the protective capacity of Goserelin compared with oral contraceptive
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's enrollment of 60 is above the median of 40 across 4,508 interventional studies indexed under Lymphoma.
Browse Lymphoma studies →University of Cologne is the lead sponsor of 199 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: 8 cycles BEACOPPesc plus oral contraceptive
Drug: 8 cycles BEACOPPesc plus Goserelin
FSH level 6 month after end of treatment
Time frame: 6 month
No study locations are listed for this record.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Cologne